For that to happen the Phase II DIPG combo trial needs to have...

For that to happen the Phase II DIPG combo trial needs to have truly impressive data in the interim analysis - impressive enough to move to the preparation of the NDA to FDA when the trial is not complete.
Time is of the essence here - the voucher will only be granted if paxalisib’s first FDA approval is in a paediatric indication.

There‘d be more time for the DIPG trial if GBM AGILE was negative for paxalisib.
But I doubt anyone here would want this. Positive GBM AGILE data should impact Kazia‘s share price in a way that a tradable FDA review voucher simply cannot.